TP53 and cancer: Despite the limited availability in clinical sample size, these suggest that the results obtained by using our cell-based model reflect reliably the clinical phenotypic aggressiveness and that the clinical phenotypes may be predisposed by the type of TP53 missense mutations and the accompanying cellular changes acquired at the very early stage of cancer development.